乙酰胆碱受体抗体在重症肌无力发展及临床诊治中的研究进展  

Research Progress of Acetylcholine Receptor Antibody in Development and Clinical Diagnosis and Treatment of Myasthenia Gravis

作　　者：周慧[1] 曾敏[1] 陈静[1] 李银萍[1] ZHOU Hui;ZENG Min;CHEN Jing;LI Yinping(Department of Neurology,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院神经内科,成都610041

出　　处：《医学综述》2023年第14期2819-2823,共5页Medical Recapitulate

摘　　要：重症肌无力(MG)是一种自身免疫性疾病,由乙酰胆碱受体(AChR)抗体(AChR-Ab)抑制神经-肌肉接头处AChR表达所致。AChR-Ab与其受体结合可导致功能性AChR丧失,并通过损害神经肌肉信号传递导致肌肉无力。虽然目前已进行大量关于AChR功能抑制的免疫病理学机制研究,但导致MG进展的因素仍不清楚。因此,未来深入研究AChR-Ab在MG发生发展中的作用机制,可以为MG的诊治提供新思路。Myasthenia gravis(MG)is an autoimmune disease caused by acetylcholine receptor(AChR)antibody(AChR-Ab)inhibition of AChR expression in neuromuscular junction.Binding of AChR-Ab to its receptor causes loss of functional AChR and leads to muscle weakness by impairing neuromuscular signaling.Although a large number of studies have been conducted on the immunopathological mechanism of AChR function inhibition,the factors leading to MG progression are still unclear.Therefore,in-depth study of the mechanism of AChR-Ab in the occurrence and development of MG can provide new ideas for the diagnosis and treatment of MG.

关 键 词：重症肌无力 乙酰胆碱受体 乙酰胆碱受体抗体 

分 类 号：R746.1[医药卫生—神经病学与精神病学]